<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00751517</url>
  </required_header>
  <id_info>
    <org_study_id>PCM 01</org_study_id>
    <nct_id>NCT00751517</nct_id>
  </id_info>
  <brief_title>Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides</brief_title>
  <official_title>Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides. A Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Parma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Parma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Systemic Necrotizing Vasculitides (SNV) encompass a group of rare diseases which include
      Wegener's Granulomatosis (WG), Churg-Strauss Syndrome (CSS), Microscopic polyangiitis
      (MPA)and Polyarteritis nodosa (PAN). Common histological findings are inflammation with
      fibrinoid necrosis of the small vessels and sporadic or absent immune-deposits. The gold
      standard therapy for SNV is currently represented by the association of Cyclophosphamide and
      Prednisone. The limits of this approach are the high frequency of recurrent disease and an
      increased incidence of malignancy and infections. The aim of the present study is to compare
      the efficacy of Methotrexate vs Cyclophosphamide for Remission Maintenance in SNV.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time from remission to relapse</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapy-related toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Wegener's Granulomatosis</condition>
  <condition>Churg-Strauss Syndrome</condition>
  <condition>Microscopic Polyangiitis</condition>
  <condition>Polyarteritis Nodosa</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cyclophosphamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methotrexate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of clinically active SNV

          -  Life-expectancy &gt; 1 year

          -  Written informed consent

        Exclusion Criteria:

          -  Creatinine clearance &lt; 10 ml/min/1.73 mq

          -  Aminotransferase levels more than twice the upper limit of the normal range

          -  HBsAg positivity

          -  anti-HCV Ig and HCV-RNA positivity

          -  HIV positivity

          -  Active malignancies

          -  Coexistence of connective tissue disease

          -  Prednisolone, cyclophosphamide or methotrexate hypersensitivity

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlo Buzio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Parma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Medicine Nephrology and Health Science, Parma University Hospital</name>
      <address>
        <city>Parma</city>
        <state>Italy/Parma</state>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992 Mar 15;116(6):488-98.</citation>
    <PMID>1739240</PMID>
  </reference>
  <reference>
    <citation>Hoffman GS. Wegener's granulomatosis. Curr Opin Rheumatol. 1993 Jan;5(1):11-7. Review.</citation>
    <PMID>8435284</PMID>
  </reference>
  <reference>
    <citation>Gordon M, Luqmani RA, Adu D, Greaves I, Richards N, Michael J, Emery P, Howie AJ, Bacon PA. Relapses in patients with a systemic vasculitis. Q J Med. 1993 Dec;86(12):779-89.</citation>
    <PMID>7906421</PMID>
  </reference>
  <reference>
    <citation>Falk RJ, Jennette JC. ANCA small-vessel vasculitis. J Am Soc Nephrol. 1997 Feb;8(2):314-22. Review.</citation>
    <PMID>9048352</PMID>
  </reference>
  <reference>
    <citation>Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, Hallahan CW, Lubensky I, Kerr GS, Hoffman GS, Fauci AS, Sneller MC. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med. 1996 Mar 1;124(5):477-84.</citation>
    <PMID>8602705</PMID>
  </reference>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2008</study_first_submitted>
  <study_first_submitted_qc>September 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2008</study_first_posted>
  <last_update_submitted>September 11, 2008</last_update_submitted>
  <last_update_submitted_qc>September 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2008</last_update_posted>
  <responsible_party>
    <name_title>Carlo Buzio</name_title>
    <organization>University of Parma</organization>
  </responsible_party>
  <keyword>Vasculitis</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Systemic Necrotizing Vasculitides</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Systemic Vasculitis</mesh_term>
    <mesh_term>Granulomatosis with Polyangiitis</mesh_term>
    <mesh_term>Microscopic Polyangiitis</mesh_term>
    <mesh_term>Churg-Strauss Syndrome</mesh_term>
    <mesh_term>Polyarteritis Nodosa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

